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more frequently in the elderly, in individuals aged
between 51 and 65 years, and in blacks with atopic
dermatitis compared with other racial groups.3-5
Although the pathogenic mechanism underlying
CNPG is not fully understood, the disease is widely
recognized as a skin reaction to continuous andCAPSULE SUMMARY
d Case series and case reports have
showed effectiveness of dupilumab in
treating chronic nodular prurigo.
d This retrospective case series
demonstrates efficacy of dupilumab in
treating chronic nodular prurigo.
Dupilumab’s effect on skin lesions, itch,
sleeplessness, and quality of life in
chronic nodular prurigo suggests that
the itch in chronic nodular prurigo is
likely mediated by the T helper 2
pathway.repeated rubbing or scratch-
ing caused by pruritus
of multifactorial origin.2
Numerous diseases have
been associated with CNPG,
including pruriginous derma-
toses (atopic dermatitis,
bullous pemphigoid, scabies,
T-cell lymphoma, dermatitis
herpetiformis, lichen planus,
psoriasis, asteatotic eczema,
and both allergic and irritant
contact dermatitis), chronic
renal failure, liver and gastro-
intestinal disease (primary
biliary cirrhosis and primary
sclerosing cholangitis), can-
cers (lymphoma, bladder car-
cinoma, and gastric cancer), infections and infestations
(HIV, hepatitis C virus, strongyloidiasis, and oxyuri-
asis), diabetes, chronic anemia, and psychiatric
disorders such as depression, anxiety, and obsessive-
compulsive disorder.1,3,6 Atopy is identified as one of
the most relevant factors to be associated with CNPG
because it occurs in approximately half of cases. CNPG
has also been proposed as a clinical variant of atopic
dermatitis, underscoring relevant similarities emerging
from atopic dermatitis and CNPG.7 Indeed, several
lines of evidence have suggested the potential role of
Th2 immunity in the pathogenesis of CNPG, and its
inhibition may result in clinically successful treatment
of CNPG patients.8-10 The intense itch experienced by
patients affected by CNPG is usually resistant to
standard treatment and associated with markedly
impaired quality of life.6 No therapy approved for
the treatment of CNPG is currently available and
off-label treatments are used, including topical
corticosteroids, topical calcineurin inhibitors, topical
capsaicin, phototherapy, and systemic agents (ie,
cyclosporine, methotrexate, antidepressants, gaba-
pentinoids, -opioid receptor antagonists, and
neurokinin 1 receptor antagonists), notwithstanding
inconsistent and often limited clinical benefit. When
CNPG is correlated with other disorders such as
infections and liver and renal diseases, specific
treatments can more effectively alleviate it.1,11,12
Dupilumab, a fully human monoclonal antibody
inhibiting the signaling pathway of both interleukin(IL) 4 and IL-13, has been recently approved for the
treatment of moderate to severe atopic dermatitis,13
and its use has been reported in CNPG case series
and case reports, showing beneficial effects on both
skin manifestations and symptoms.14-24
We performed a multicenter study to describe
dupilumab effectiveness and tolerability in treatingadult patients with CNPG re-
fractory to both topical and
systemic therapies, during
an observation period of
36 weeks.
PATIENTS AND
METHODS
This retrospective, multi-
center study included adult
patients ($18 years) affected
by CNPG who were treated
with dupilumab for at least
16 weeks during April 2018
to August 2019. The study
population consisted of
patients referred to dermato-
logic outpatient clinics of the3 involved University centers: Catholic University of
Rome, University of Verona, and University of
Campania ‘‘Luigi Vanvitelli,’’ Naples, Italy.
Diagnosis was based on the following criteria:
chronic pruritus ($6 weeks), history or signs of
repeated scratching (eg, excoriations, scars), and
localized or generalized presence of multiple pruri-
ginous lesions (definition of pruriginous lesion:
excoriated, scaling, or crusted papules, and nodules
or plaques, often with a whitish or pink center and
hyperpigmented border).2
For each patient, demographic and clinical data
(ie, sex, age, height, weight, body mass index, waist
circumference, personal and family history of CNPG,
age at CNPG onset, anatomic site of skin lesions,
disease duration, atopic manifestations, other co-
morbidities, previous and current treatments, and
medications) were obtained from the database of
each clinic. Patients were treated with subcutaneous
injections of dupilumab at the labeled dose for atopic
dermatitis, 600 mg at baseline followed by 300 mg
every 2 weeks. Any adverse event, patient’s decision,
or unresponsiveness constituted cause for treatment
interruption.
In cases not associated with atopic dermatitis,
dupilumab was prescribed with the approved dose
for atopic dermatitis. Visits were performed at
baseline, week 4, week 16, and then every 20 weeks.
At each visit, including baseline and follow-up visits,
disease severity was assessed by (1) the Investigator
Table I. Baseline characteristic and demographics
Total patients 27
Men/women 11/16
Mean age (SD), y 52.0 (15.9)
Mean BMI (SD) 25.6 (3.4)
History of AD or AD manifestations 13/27
Family history of AD 8/27
Allergic rhinitis 14/27
Asthma 6/27
Allergic conjunctivitis 3/27
Diabetes 5/27
Hypertension 6/27
Hypothyroidism 2/27
Psychiatric disorders 8/27
Obesity 3/27
Mean age at CNPG onset, y 40.5 (16.3)
Mean CNPG duration, y 13.7 (13.6)
Mean baseline IgE serum levels, IU/mL 423.1
Patients with[1 previous systemic treatment 27/27
Patients with[2 previous systemic treatments 19/27
AD, Atopic dermatitis; BMI, body mass index; CNPG, chronic
nodular prurigo; Ig, immunoglobulin; SD, standard deviation.
Abbreviations used:
CNPG: chronic nodular prurigo
DLQI: Dermatology Life Quality Index
IGA: Investigator Global Assessment
IL: interleukin
NRS: numeric rating scale
SD: standard deviation
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in Supplemental Fig 1 (Supplemental Figures avail-
able via Mendeley at https://doi.org/10.17632/
38h7p8kjp3.1), classifying disease severity as no
disease (0), very mild (1), mild (2), moderate (3),
severe (4), and very severe (5); (2) a 0-to-10 numeric
rating scale (NRS) for itch; (3) a 0-to-10 NRS for
sleeplessness; and (4) the Dermatology Life Quality
Index (DLQI). On a paper 0-to-10 visual scale,
patients marked their score estimation for both itch
and sleeplessness NRS.
Times and DLQI and NRS itch scores were
established according to requirements of the regula-
tory Italian agency for drug prescription (Italian
Agency for Drugs). We used the IGA and NRS for
sleeplessness scores to implement the assessment of
CNPG severity. Safety was evaluated by treatment-
emergent adverse events, physical examinations,
and laboratory monitoring. The study was approved
by each local ethical committee and conducted
in accordance with the Declaration of Helsinki
guidelines.
Statistical analyses
Descriptive statistics were calculated for each
demographic and clinical variable, using frequencies
and percentage for categoric variables and
mean 6 standard deviation (SD) for continuous
ones. x2 Test or Fisher’s exact test was used as
appropriate for categoric variables. t Test or Mann-
Whitney U test was used as appropriate for contin-
uous variables. To verify any significant difference of
clinical response between atopic dermatitiserelated
CNPG and atopic dermatitiseunrelated patient sub-
cohorts, Fisher’s exact test was used as appropriate
for IGA score modifications, and Mann-Whitney U
test as appropriate for DLQI, NRS for itch, and NRS
for sleeplessness score modifications at weeks 4, 16,
and 36. In all cases, P\ .05 was considered statis-
tically significant.
RESULTS
Twenty-seven white CNPG patients, 11 men and
16 women, treated with dupilumab were included in
the study. Patients’ demographic and clinical char-
acteristics are illustrated in Table I. Mean age was52.0 years (SD 15.9 years; minimum age 23 years;
maximum age 83 years) and mean age of CNPG
onset was 40.54 years (SD 16.3 years), with mean
disease duration of 13.7 years (SD 13.6 years).
Thirteen of 27 patients (48.1%) had a history of
atopic dermatitis or concomitant atopic dermatitis
manifestations, 5 had no atopic dermatitis but had
other atopic manifestations (allergic rhinitis, asthma,
and conjunctivitis), and 9 (33.3%) had no atopic
manifestations.
All patients had been previously treated with at
least 1 systemic treatment, and 13 of 27 failed at least
3 systemic treatments before dupilumab therapy.
Cyclosporine and oral corticosteroids were the most
commonly used therapies before dupilumab
treatment (22/27 and 19/27, respectively). Other
previously performed therapies included photother-
apy (12/27), methotrexate (8/27), and azathioprine
(7/27). Baseline disease severity, assessed by a 0-to-5
IGA score, was classified as IGA score 4 in 11 of 27
patients and IGA score 5 in 16 patients (Fig 1). Mean
baseline values for the NRS for itch and sleeplessness
were 8.9 (SD 1.0) and 8.2 (SD 2.0), respectively. All
patients had both NRS itch and sleeplessness values
greater than 7. The mean baseline DLQI score for
quality of life was 21.0 (SD 4.0).
At week 4, clinical improvement was assessed by
IGA and showed a reduced number of patients with
CNPG scores of 5 (7) and 4 (2) (Fig 1). Fourteen of 27
patients (51.8%) achieved at least a 2-grade reduction
in IGA score. Significant reduction of both itch and
sleeplessness NRS values (from 8.9 to 6.3 and from
Fig 1. Disease severity assessed by the Investigator Global Assessment scale at different times.
A progressively lower number of patients with Investigator Global Assessment score 4 or 5
were observed throughout the observation period. IGA, Investigator Global Assessment.
Fig 2. Improvement of both symptoms and patients’ quality of life during dupilumab therapy.
Reduction of the numeric rating scale score for itch and sleeplessness, and of the Dermatology
Life Quality Index score, at weeks 4, 16, and 36. Score reductions for each tool were significant
at all points compared with baseline values. Statistical analysis was performed with the Student
t test. DLQI, Dermatology Life Quality Index; NRS, numeric rating scale.
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majority of patients and was associated with a DLQI
score reduction (from 21.0 to 11.8; P\.001) (Fig 2).
Four of 27 patients interrupted therapy for lack of
efficacy or worsening of CNPG after 4 weeks of
therapy.
A consistent proportion of patients (23/27; 85.2%)
had at least 16-week continuous treatment andachieved IGA score 1 (11/23; 47.8%) or 2 (5/23;
21.7%). An increased number of patients achieved at
least a 2-grade reduction in IGA score (19/23; 82.6%).
NRS values for itch and sleeplessness decreased from
8.9 to 2.7 and from 8.2 to 1.7, respectively (P\.001).
Ten patients achieved 36 weeks of continuous
treatment while maintaining clinical efficacy (Figs 1
and 2). Treatment response did not differ between
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We did not detect any meaningful difference in terms
of itch amelioration, sleep improvement, and
DLQI score reduction between atopic
dermatitiserelated CNPG (Supplemental Fig 2) and
atopic dermatitiseunrelated patient subcohorts
(Supplemental Fig 3). Dupilumab treatment
response appeared to be faster in patients with
atopic dermatitiserelated CNPG (Supplemental Fig
2) compared with atopic dermatitiseunrelated
CNPG in terms of IGA score reduction
(Supplemental Fig 3). Along these lines, the same
number of patients who dropped out (2 patients in
each subcohort) was observed.
Overall, treatment-emergent adverse events con-
sisted of 8 cases of mild conjunctivitis treated with
tear substitutes and corticosteroid eyedrops (fluoro-
metholone 0.1%), but none caused treatment
interruption. Three of 8 patients had a history of
conjunctivitis before dupilumab therapy, and 7 of
them presented with rhinitis, 4 with asthma, and 5
with atopic dermatitiseassociated CNPG. In 1 patient
with CNPG associated with depression, who was
under treatment with antidepressants, dupilumab
therapywas discontinued after 16weeks of treatment
because of the occurrence of hepatotoxicity caused
by an increased dosage of antidepressants. However,
the patient was re-treated after 8-week withdrawal.
DISCUSSION
CNPG is amultifactorial skin disease characterized
by chronic itch (lastingmore than 6weeks), history or
signs of prolonged scratching behavior, and multiple
localized or generalized nodular lesions thatmight be
associated with 1 or more underlying conditions
causing pruritus.1,2,6,7,25 This suggests that chronic
pruritus induced by different causes leads to an itch-
scratch cycle characterized by a neuronal sensitiza-
tion with subsequent development of the typical
nodular and excoriated skin lesions.6,7,25 In one
survey of patients with CNPG, an association with
dermatologic, neurologic, and mixed disorders was
found in 87% of patients and included dermatologic
(19%), systemic (7%), neurologic (2%), and mixed-
origin (59%) diseases.7 In line with previous obser-
vations, our study showed that approximately 50% of
patients (13/27) had a history of atopic dermatitis,
whereas 5 patients had a family history of atopic
dermatitis or concomitant atopic comorbidities,
including asthma, conjunctivitis, and rhinitis. Cases
with atopic dermatitis predisposition can be consid-
ered prurigolike atopic dermatitis that is currently
recognized as a clinical variant of atopic dermatitis.26
Nevertheless, CNPG unrelated to atopic dermatitis
may also benefit from dupilumab therapy becausepathogenic evidence linking CNPG to the Th2
pathway has been reported. Although CNPG
pathogenesis is not fully understood, an emerging
pathogenic role of the Th2 signaling has been
suggested.8-10 Sonkoly et al9 showed significant
upregulation of IL-31, one of the Th2-signature
cytokines involved in the pathogenesis of pruritus
and inflammation in CNPG lesions compared with
healthy skin. Overexpression of another Th2-derived
cytokine, namely, IL-4, was detected in CNPG
lesional skin.8 Additionally, CNPG lesional skin
showed an increased keratinocyte nuclear
expression of phosphorylated signal transducer and
activator of transcription6, a key transcriptional factor
mediatingTh2 signaling.10Amurinemodel of chronic
itch suggested the contribution of both IL-4 and IL-13
in stimulating itch-sensory neuronal pathways
through IL-4Ra and IL-13Ra1 receptor, and Janus
kinase 1 signaling. The expression of receptors bind-
ing to Th2 cytokines inmurine-sensitive neurons was
confirmed in human dorsal root ganglia and direct
activation of sensorial neurons by IL-4 and IL-13.27
All the above-mentioned evidence supports the
use of dupilumab in treating CNPG, whether associ-
ated with atopic dermatitis or not.16,24 In our study,
no difference in response to treatment was detected
in atopic dermatitis patients with CNPG compared
with patients with atopic dermatitiseunrelated
CNPG, representing approximately half of our
study population (14/27). Itch amelioration, sleep
improvement, and DLQI score reduction were
similar between atopic dermatitiserelated CNPG
and atopic dermatitiseunrelated patient subcohorts,
whereas in terms of IGA score reduction, dupilumab
treatment response appeared to be faster in patients
with atopic dermatitiserelated CNPG comparedwith
atopic dermatitiseunrelated CNPG. Nevertheless,
the limited number of patients for each subcohort
did not allow any further statistical analysis and this
faster IGA score reduction in patients with atopic
dermatitiserelated CNPG was not consistent with
the other findings. In addition, most patients (8/10)
achieving 36 weeks of treatment had no history of
atopic dermatitis. Overall, dupilumab was proven
effective in rapidly improving itch and sleeplessness,
with early score reduction in both dedicated NRS
measures that was detected after 4 weeks, with
a progressive amelioration at weeks 16 and 36.
Symptom improvement was associated with reduc-
tion of erythema and infiltration of CNPG lesions, as
demonstrated by the increasing number of patients
with reduced IGA score throughout the observation
period. We observed response to dupilumab therapy
as early as week 4, obtaining amelioration of itching,
disease severity, and quality of life. This finding
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itching and DLQI score in dupilumab-treated CNPG
patients, detected during the first weeks of ther-
apy.15,16,24 Zhai et al17 reported a rapid improvement
of itch after the first 2 weeks of dupilumab therapy,
showing a mean reduction of NRS itch intensity of
7.89 (SD 2.93; mean baseline NRS itch intensity 9.11,
SD 1.05). Almustafa et al16 investigated pruritus and
quality of life in 3 patients, using an itch intensity
score, itch-related quality of life, and DLQI. A
marked and sustained improvement of DLQI score
was observed by week 2, whereas itch intensity and
itch-related quality of life improved by week 4.
Napolitano et al19 described a rapid and marked
reduction of both DLQI and pruritus visual analog
scale scores after 16-week dupilumab therapy (mean
baseline DLQI score 18.6 [SD 5.26] versus 3 [SD 2.34]
at week 16, P \ .001; mean baseline pruritus VAS
score 9.15 [SD 0.88] versus 2.75 [SD 0.7] at week 16,
P\.001) in 9 dupilumab-treated CNPG patients. Our
population showed similar mean baseline values of
both DLQI score (baseline 21.0 [SD 4.0]) and NRS itch
score (8.9 [SD 1.0]), which decreased to 4.6 and 2.7,
respectively, achieving values at week 16 in line with
those of this previously published study.19
After 16 weeks of treatment, most patients (17/24;
70.8%) were classified as having mild or very mild
scores (IGA score 1/2), and 3 of 10 patients achieved
36 weeks of therapy with complete remission.
Additionally, treatment effectiveness on pruritus
and skin manifestations led to an improvement of
quality of life (DLQI score reduction). Treatment
response wasmaintained as long as after 36 weeks of
therapy, similar to results of a recent multicenter
study considering retrospectively 16 patients
affected by CNPGwhowere treated with dupilumab,
and reporting clinical response over pruritus at
3 months (NRS score for itch median from 8.5 to
3.0) and a subsequent reduction of skin lesions, with
50% of patients (6/12) experiencing total remission
of disease at 6 months.24
Dupilumab was demonstrated to be safe in our
population of patients affected by CNPG because no
serious treatment-emergent adverse events were
reported. The most common adverse event was
conjunctivitis (8/27; 29.6%), occurring within the
first weeks of therapy (reported at week 4 by 7 of 8
patients). All cases of conjunctivitis were mild and
resolved with topical therapy without interrupting
dupilumab treatment.28 This rate of conjunctivitis
observed in our population is in line with clinical
outcomes derived from trials testing efficacy and
safety of dupilumab for the treatment of atopic
dermatitis patients, which detected conjunctivitis in
up to 28% of dupilumab-treated patients.29-31Although our study included the largest CNPG pop-
ulation, to our knowledge, who were undergoing
dupilumab therapy, it has some limitations. First,
there was no validated severity assessment tool at the
initial data collection. This limitation was also
detected among other clinical studies evaluating
dupilumab response in CNPG patients because there
was no consistency in the methods and assessment
tools used. Studies evaluated efficacy with different
tools and at different times, underscoring a lack of
both validated and simple tools for the assessment of
CNPG severity. Second, the limited cohort of treated
patients allowed only a descriptive analysis of the
data. Third, the study was limited by the short-term
observation period considered.
In conclusion, in our cohort of 27 CNPG patients,
dupilumab was proven effective in reducing itch
and improving CNPG skin lesions. Demonstrating
dupilumab effectiveness in treating CNPG in
patients without an atopic background, this study
may provide additional evidence of a potential
pathogenic role of the Th2 pathway in mediating
itching in CNPG, regardless of the association with
atopic dermatitis. Placebo-controlled randomizedpro-
spective studies are under way to definitively describe
the therapeutic value of dupilumab in CNPG patients.REFERENCES
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